11/15
11:11 am
alt
Altimmune Presents New Data on the Effect of Pemvidutide on Inflammatory Lipids in Subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) at The Liver Meeting® 2024 [Yahoo! Finance]
Low
Report
Altimmune Presents New Data on the Effect of Pemvidutide on Inflammatory Lipids in Subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) at The Liver Meeting® 2024 [Yahoo! Finance]
11/15
11:00 am
alt
Altimmune Presents New Data on the Effect of Pemvidutide on Inflammatory Lipids in Subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) at The Liver Meeting® 2024
Low
Report
Altimmune Presents New Data on the Effect of Pemvidutide on Inflammatory Lipids in Subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) at The Liver Meeting® 2024
11/14
08:15 am
alt
Altimmune, Inc. (NASDAQ: ALT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $12.00 price target on the stock.
High
Report
Altimmune, Inc. (NASDAQ: ALT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $12.00 price target on the stock.
11/13
02:26 am
alt
Altimmune Inc (ALT) Q3 2024 Earnings Call Highlights: Strategic FDA Alignment and Expanding ... [Yahoo! Finance]
Medium
Report
Altimmune Inc (ALT) Q3 2024 Earnings Call Highlights: Strategic FDA Alignment and Expanding ... [Yahoo! Finance]
11/12
07:31 am
alt
Altimmune, Inc. (NASDAQ: ALT) is now covered by analysts at UBS Group AG. They set a "buy" rating and a $26.00 price target on the stock.
High
Report
Altimmune, Inc. (NASDAQ: ALT) is now covered by analysts at UBS Group AG. They set a "buy" rating and a $26.00 price target on the stock.
11/12
07:00 am
alt
Altimmune Announces Third Quarter 2024 Financial Results and Provides a Business Update
High
Report
Altimmune Announces Third Quarter 2024 Financial Results and Provides a Business Update
11/11
07:30 am
alt
Altimmune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Altimmune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
11/11
07:30 am
alt
Altimmune Appoints Life Sciences Industry Veteran Greg Weaver as Chief Financial Officer
Medium
Report
Altimmune Appoints Life Sciences Industry Veteran Greg Weaver as Chief Financial Officer
11/7
07:30 am
alt
Altimmune Announces Successful Completion of End-of-Phase 2 Meeting with FDA for Pemvidutide in the Treatment of Obesity
Low
Report
Altimmune Announces Successful Completion of End-of-Phase 2 Meeting with FDA for Pemvidutide in the Treatment of Obesity
11/6
07:30 am
alt
Altimmune to Participate at Two Upcoming Investor Conferences
Low
Report
Altimmune to Participate at Two Upcoming Investor Conferences
11/4
07:30 am
alt
Altimmune to Report Third Quarter 2024 Financial Results and Provide Business Update on November 12, 2024
Low
Report
Altimmune to Report Third Quarter 2024 Financial Results and Provide Business Update on November 12, 2024
10/17
11:31 am
alt
Altimmune, Inc. (ALT): A Bull Case Theory [Yahoo! Finance]
Low
Report
Altimmune, Inc. (ALT): A Bull Case Theory [Yahoo! Finance]
10/15
08:00 am
alt
Altimmune to Present New Data on the Lipidomic Profile in Subjects Treated with Pemvidutide at The Liver Meeting® 2024
Medium
Report
Altimmune to Present New Data on the Lipidomic Profile in Subjects Treated with Pemvidutide at The Liver Meeting® 2024
10/2
02:49 pm
alt
Consider Buying Potential Takeover Target Altimmune [Seeking Alpha]
Low
Report
Consider Buying Potential Takeover Target Altimmune [Seeking Alpha]
10/1
07:30 am
alt
Altimmune to Participate in the H.C. Wainwright 8th Annual MASH Virtual Conference
Low
Report
Altimmune to Participate in the H.C. Wainwright 8th Annual MASH Virtual Conference
9/30
07:30 am
alt
Altimmune Completes Enrollment in Phase 2b IMPACT Trial of Pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Medium
Report
Altimmune Completes Enrollment in Phase 2b IMPACT Trial of Pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis (MASH)
9/10
01:09 pm
alt
CORRECTION – Altimmune Presents Results of a Phase 2 MRI-Based Body Composition Sub-Study at 60th Annual Meeting of the European Association for the Study of Diabetes
Low
Report
CORRECTION – Altimmune Presents Results of a Phase 2 MRI-Based Body Composition Sub-Study at 60th Annual Meeting of the European Association for the Study of Diabetes
9/10
07:59 am
alt
Altimmune Presents Results of a Phase 2 MRI-Based Body Composition Sub-Study at 60th Annual Meeting of the European Association for the Study of Diabetes [Yahoo! Finance]
Medium
Report
Altimmune Presents Results of a Phase 2 MRI-Based Body Composition Sub-Study at 60th Annual Meeting of the European Association for the Study of Diabetes [Yahoo! Finance]
9/10
07:45 am
alt
Altimmune Presents Results of a Phase 2 MRI-Based Body Composition Sub-Study at 60th Annual Meeting of the European Association for the Study of Diabetes
Medium
Report
Altimmune Presents Results of a Phase 2 MRI-Based Body Composition Sub-Study at 60th Annual Meeting of the European Association for the Study of Diabetes
9/3
07:30 am
alt
Altimmune Announces Oral Presentation of Pemvidutide Clinical Data at 60th Annual Meeting of the European Association for the Study of Diabetes
Medium
Report
Altimmune Announces Oral Presentation of Pemvidutide Clinical Data at 60th Annual Meeting of the European Association for the Study of Diabetes